Related Experiment Video
Updated: Aug 15, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
Published on: August 16, 2024
Pharmacokinetic/Pharmacodynamic Analysis of Quinidine-Induced Dominant Frequency Reduction in Thoroughbred Horses
Taisuke Kuroda1,2, Yohei Minamijima3, Yuji Takahashi4
1Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Shimotsuke, Japan.
Abstract:
Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory Emax model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06-Hz reduction in DF. A model-predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Pharmacodynamic Models: Linear Concentration–Effect Model
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

